CPC A61K 39/39591 (2013.01) [A61K 9/08 (2013.01); A61K 9/19 (2013.01); A61K 39/3955 (2013.01); A61K 47/10 (2013.01); A61K 47/18 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); C07K 16/2866 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 14/7155 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)] | 30 Claims |
1. A method of treating a subject affected with an IL-31-associated disorder, the method comprising administering to the subject by injection or infusion a solution formulation comprising:
6 to 100 mg/mL of an IL-31 antagonist that is an anti-IL-31RA antibody comprising (i) an H chain variable region that comprises a CDR1 as set forth in SEQ ID NO: 1, a CDR2 as set forth in SEQ ID NO: 2, and a CDR3 as set forth in SEQ ID NO: 3; and (ii) an L chain variable region that comprises a CDR1 as set forth in SEQ ID NO: 4, a CDR2 as set forth in SEQ ID NO: 5, and a CDR3 as set forth in SEQ ID NO: 6,
6 to 20 mmol/L Tris buffer,
45 to 150 mmol/L arginine or a salt thereof,
75 to 250 mmol/L sucrose or trehalose, and
0.15 to 0.50 mg/mL poloxamer 188 or polysorbate 20,
wherein the solution formulation has a pH in the range of 6 to 8.
|